Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 09/16/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market TodayZacks Investment Research • 09/10/26
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?Zacks Investment Research • 09/04/26
Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook?Zacks Investment Research • 09/03/26
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes PharmaZacks Investment Research • 08/17/26
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline UpdatesMarketBeat • 08/17/26
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference TranscriptSeeking Alpha • 08/11/26
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/26
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery ProgramGlobeNewsWire • 08/05/26
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewsWire • 07/31/26
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to KnowZacks Investment Research • 07/29/26
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5thGlobeNewsWire • 07/29/26
Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market TodayZacks Investment Research • 07/14/26
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader MarketZacks Investment Research • 07/08/26
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?The Motley Fool • 07/04/26
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?The Motley Fool • 07/03/26